entertainment -WSS

entertainment

author：comprehensive 2025-09-27 14:10:36 - browse：496

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Fetal cell organoids grown from amniotic fluid, study finds

WSS

Hospitals, health systems can help patients avoid medical debt

Streamlined flu vaccines recommended by FDA advisory panel

VC firm RA Capital starts a new synthetic biology incubator

A new approach to psychiatric drug development

CDC: Cases of alpha

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

hotspot

entertainment

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Stoke drug shows lower activity against childhood epilepsy

Alkermes shareholders re

Hospitals, health systems can help patients avoid medical debt

Alkermes shareholders re

Medicare drug price negotiation continues, as pharma counteroffers

After affirmative action ruling, medical educators look to 'holistic review'

Immune cells and nerve overgrowth may explain recurring UTI pain

BioMarin wins approval for gene therapy to treat hemophilia A

Families look for replacement for GSK asthma drug Flovent

focus

Readout Newsletter: BridgeBio, Akero, and human embryo models

Behind warning on Apellis’s eye drug lies a conflict of interest

As the dark side of IVF slowly comes into focus, even more transparency is needed

Ozempic has benefits for kidney disease as well as diabetes

First over

The public health thinking behind the CDC’s new Covid guidance

hotspot

focus

explore

hotspot